Tunç is currently the Chief Operating Officer of Galen Therapeutics, a regenerative medicine company focusing on pain prevention in CNS applications.
Prior, Tunç was the head of program management and general manager for 3 assets at Mana Therapeutics, a company focusing on allogeneic TCR based cell therapies in liquid and solid tumor applications.
Prior to Mana, Tunç was the head of SmartTrials at Foundation Medicine, helping precision oncology sponsors conduct clinical research and development with deep molecular diagnostics data.
Prior, Tunç led consulting services at ZS Associates, IQVIA and Deloitte Consulting working with biotechnology / pharmaceutical sponsors helping improve R&D and commercial operations.
Tunç’s academic background includes a MS in Biotechnology with training in advanced Immunology from the Johns Hopkins University, and an MBA and BS in Mechanical Engineering both from Duke University